Wel­come Case­bia, the $335M gene edit­ing JV hatched by Bay­er and CRISPR Ther­a­peu­tics

The new gene edit­ing joint ven­ture be­ing formed by Bay­er and CRISPR Ther­a­peu­tics is tak­ing shape. Now dubbed Case­bia Ther­a­peu­tics, the fledg­ling op­er­a­tions has be­gun …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER